Skip to content

Announces Health Canada Approval PrBeteflam for Plaque Psoriasis

Cipher Receives Health Canada Approval of (Pr)Beteflam. (NASDAQ: CPHR; TSX:CPH) ( Cipher or the Company ) today announced that Health Canada has approved PrBeteflam (betamethasone valerate topical patch), a novel, patent-protected treatment of mild to moderate plaque psoriasis of the elbows and knees for a maximum duration of 30 days in adult patients. Cipher Pharma (CPHR) Announces Health Canada Approval PrBeteflam for Plaque Psoriasis. December 7, 2015 7:58 AM. Cipher Pharmaceuticals Inc. (CPHR) Announces Health Canada Approval PrBeteflam for Plaque.

Announces Health Canada Approval PrBeteflam for Plaque Psoriasis 2Cipher Pharma (CPHR) Announces Health Canada Approval PrBeteflam for Plaque. Today announced that Health Canada has approved PrBeteflam™ (betamethasone valerate topical patch), a novel, patent-protected treatment of mild to moderate plaque psoriasis of the elbows and knees for a maximum duration of 30 days in adult patients. Pharma (CPHR) Announces Health Canada Approval PrBeteflam for Plaque.

Cipher Pharma (CPHR) Announces Health Canada Approval PrBeteflam for Plaque. (CPHR) Announces Health Canada Approval PrBeteflam for Plaque. LEO Pharma Inc. Debuts LEO(R) Quality Care Program for Plaque Psoriasis Patients. Pharma (CPHR) Announces Health Canada Approval PrBeteflam for Plaque.

Cipher Pharmaceuticals Inc: Tse:cph Market News

Announces Health Canada Approval PrBeteflam for Plaque Psoriasis 3Cipher Pharma (CPHR) Announces Health Canada Approval. Cipher Pharma (CPHR) Announces Health Canada Approval PrBeteflam for Plaque. The scaly patches commonly caused by psoriasis, called psoriatic plaques, are areas of inflammation and excessive skin production. Codorus Valley Bancorp Inc. (NASDAQ:CVLY) announced it has commenced an underwritten public offering of approximately 30. (NASDAQ:CPHR) announced that Health Canada has approved PrBeteflam (betamethasone valerate topical patch), a novel, patent-protected treatment of mild to moderate plaque psoriasis of the elbows and knees for a maximum duration of 30 days in adult patients. (NASDAQ: CPHR; TSX:CPH) ( Cipher or the Company ) today announced that Health Canada has approved PrBeteflam (betamethasone valerate topical patch), a novel, patent-protected treatment of mild to moderate plaque psoriasis of the elbows and knees for a maximum duration of 30 days in adult patients. View Cipher Pharmaceuticals’s latest equities research coverage, earnings and dividend announcements and insider trades at MarketBeat.com.

Findata: News For Tse, Dnd

You can find free articles related to Plaque Psoriasis. Provided courtesy of Psoriasis Guide. Cipher Pharma (CPHR) Announces Health Canada Approval PrBeteflam for Plaque.